Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
US11406627B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 11, 2018 |
| Grant date | Aug 9, 2022 |
| Priority date | — |
| Expiry date | Oct 19, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical combination comprising (a) an MDM2 inhibitor and (b) an ERK inhibitor, for use in the treatment of a cancer. This invention relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination; and kits and/or packages containing such combinations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.